FDA approves first new class of treatment for schizophrenia in 30 years

The U.S. Food and Drug Administration (FDA) on Sept. 26 approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for treating adult patients with schizophrenia. The move represents the first new class of treatment for this population in three decades.